Kwarlay.com

Navigating the News Maze with Clarity

Medicine

The Affects of ENV-101 on IPF

John Hood, CEO, Endeavor BioMedicines discusses the key differences between ENV-101 and currently approved IPF treatments.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *